CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · Science & Nature

Cilazapril

chemical compound

Specimen drawers, botanical folios and brass scientific instruments under study light
Science and natureInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionDec 23, 2025
Entity authorityQ867350 ↗
Source-derived summary

Cilazapril is an angiotensin-converting enzyme inhibitor (ACE inhibitor) used for the treatment of hypertension and congestive heart failure.

It was patented in 1982 and approved for medical use in 1990.

Chemistry

Of the eight possible stereoisomers, only the all-(S)-form is medically viable.

Brand names

It is branded as Dynorm, Inhibace, Vascace and many other names in various countries. None of these are available in the United States as of May 2010.

Editorial summary

“Cilazapril” enters the record as chemical compound. Crown Archives preserves that source wording while asking what Cilazapril, chemical and compound can confirm, complicate or overturn.

Editorial reviewA practical orientation to terminology and classification, particularly when read beside dated observations, specimens or technical literature. The current lead gives the account dated anchors—1982, 1990, 2010—that can be checked directly. The selected authority fields contribute no independent date. Its strongest next move is a source search built around Cilazapril, chemical and compound.
Editorial analysis

Why this record matters

“Cilazapril” is worth following because a concise public description often conceals a longer documentary argument. Here, Cilazapril, chemical and compound provides the most credible route into that argument.

Evidence profile

Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated Dec 23, 2025. The linked authority identifier is Q867350. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1982, 1990 and 2010.

Critical limits

Current terminology should not be projected backward without checking the classification used when the underlying evidence was created. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.

Best used for
  • Current terminology
  • Classification context
  • Finding cited technical literature
Verify next

Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.

Three-step research path

  1. Establish the record: confirm the title “Cilazapril”, its source revision and the description used here.
  2. Expand the search: follow Cilazapril primary sources, Cilazapril archive and Cilazapril research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Cilazapril”?
  2. Has classification or technical consensus changed since the cited source?
  3. Which observation, specimen, dataset or publication supports the account?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “Cilazapril” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.